AI Agents & AutomationforPharmaceuticals

AI Agents & Automation for Pharmaceuticals

Pharma workflows are precise, evidence-bound, and validated: pharmacovigilance case processing, regulatory submission assembly, and evidence synthesis all follow defined procedures under GxP and FDA expectations. Agents can do this multi-step work, but only inside validated boundaries where every action is documented and every conclusion is sourced. arosplatforms builds agents that plan a case or submission workflow, call your validated systems through scoped connections, and pause for qualified human review where regulation demands it. Because every plan, tool call, and source is traced and the system runs in your own controlled environment, you get automation that fits a validated quality system instead of breaking it.

Book a consultation All Pharmaceuticals AI

How we deliver it

AI Agents & Automation, built for pharmaceuticals

We design agents to operate inside your validated environment, with documented behavior, defined inputs and outputs, and traceability that supports GxP and computer system validation.

We make qualified human review a required gate on any regulated output, so agents assemble and draft but never finalize a safety assessment or submission element on their own.

We ground every output in cited source documents, so evidence synthesis and case narratives are auditable back to their references rather than generated from thin air.

We integrate through scoped, audited connections to your safety database, document management, and submission systems, all hosted in your own controlled cloud.

Where it pays off in pharmaceuticals

Adverse event intake

An agent intakes and structures adverse event reports, drafts the case narrative with sources, and routes it to a safety reviewer, never closing a case itself.

Submission assembly

The agent compiles documents and checks them against submission requirements and formatting rules, flagging gaps for regulatory affairs to resolve.

Evidence synthesis

For literature and evidence reviews, the agent gathers and summarizes findings with every claim cited back to its source for a reviewer to verify.

Literature monitoring

The agent monitors literature for safety signals on relevance criteria, surfacing candidate cases to pharmacovigilance instead of deciding signal status.

Pharma teams typically process pharmacovigilance cases and assemble submissions significantly faster, with every agent action documented and traceable for GxP and FDA inspection.

Pharmaceuticals AI, answered

Yes, when they are built for it. We design agents with documented behavior, defined inputs and outputs, and full traceability so they fit computer system validation. Every action is recorded, and qualified humans approve any regulated output.

We ground every output in cited source documents, so a reviewer can trace each statement back to its reference. The agent never asserts a conclusion without a source, which keeps narratives and reviews auditable rather than speculative.

No. Agents do the assembly, drafting, and checking, but finalizing a safety assessment or submission element is always a qualified human gate. The reviewer makes the regulated decision, and the approval is part of the record.